Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Circulatory Exercise After Total Knee Replacement

3 de julio de 2026 actualizado por: Mariam ibrahim, Assiut University

Boosting Venous Return After Knee Replacement: Effects of a Novel Circulatory Exercise on Early Postoperative Inflammation - A Randomized Controlled Trial

Total knee replacement is commonly associated with early postoperative inflammation, edema, pain, and reduced mobility. This randomized controlled trial will evaluate whether adding a simple circulatory exercise program to standard postoperative rehabilitation reduces early limb edema and inflammatory response after unilateral primary total knee replacement. Participants will be randomized to standard rehabilitation alone or standard rehabilitation plus seated and supine knee-extension exercises with alternating ankle dorsiflexion. The primary endpoint is change in limb edema measured by standardized limb circumference at postoperative day 14.

Descripción general del estudio

Descripción detallada

This is a randomized, parallel-group, assessor-blinded controlled clinical trial. Adults undergoing elective unilateral primary total knee replacement for osteoarthritis will be allocated in a 1:1 ratio to either standard postoperative rehabilitation or standard rehabilitation plus a circulatory exercise protocol. The intervention includes supine leg elevation with ankle pump and knee extension, and seated knee extension with alternating ankle dorsiflexion. The exercise will be performed at approximately 15 cycles per minute, 10 sets of 1 minute, with 60 seconds rest between sets, twice daily for 14 postoperative days. Outcomes include limb circumference, pain, functional mobility, quadriceps strength, inflammatory biomarkers, hemostasis markers, analgesic use, patient satisfaction, and adverse events.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

68

Fase

  • No aplica

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • Adults ≥ 18 years undergoing elective unilateral primary TKR for osteoarthritis.
  • Able to provide informed consent.
  • Able to perform the exercise (cognitively and physically) prior to discharge.

Exclusion Criteria:

  • Preexisting peripheral vascular disease with severe ischemia or venous insufficiency that limits exercise.
  • Contraindication to early active movement per surgeon (e.g., complex surgical fixation limiting motion if present).
  • Severe neurological or cognitive impairment preventing instruction adherence.
  • Inability to comply with follow-up.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: standard postoperative TKR rehabilitation (hospital protocol)
Participants will receive standard postoperative total knee replacement rehabilitation according to the local hospital protocol, including early mobilization, ROM exercises, quadriceps activation, ambulation training, and standard pain/edema management as clinically indicated.
Experimental: Circulatory Exercise Protocol (in addition to standard rehab)
Participants will receive standard postoperative rehabilitation plus a circulatory exercise protocol including supine leg elevation with ankle pump and knee extension, and seated knee extension with alternating ankle dorsiflexion. The exercise will be performed at approximately 15 cycles/minute, 10 sets of 1 minute, 60 seconds rest between sets, twice daily for 14 postoperative days.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Difference in postoperative lower-limb edema between the operated and contralateral limbs measured by standardized limb circumference (cm)
Periodo de tiempo: Baseline/preoperative to postoperative day 14
Lower-limb circumference (cm) will be measured bilaterally at standardized anatomical landmarks: 10 cm above the superior border of the patella, at the mid-patellar level, and 20 cm above the superior border of the patella. Measurements will be obtained on both the postoperative limb and the contralateral (sound) limb. Edema will be quantified as the side-to-side difference in circumference and the change from baseline.
Baseline/preoperative to postoperative day 14

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Postoperative pain intensity measured by the Numeric Rating Scale (NRS, 0-10) at rest and during activity
Periodo de tiempo: Baseline/preoperative to postoperative day 14
Pain intensity will be assessed using an 11-point Numeric Rating Scale (NRS), where 0 indicates no pain and 10 indicates the worst imaginable pain. Scores will be recorded at rest and during activity.
Baseline/preoperative to postoperative day 14
Functional mobility:
Periodo de tiempo: Baseline/preoperative to postoperative day 14

Timed Up and Go (TUG) (go for 3 meter and come back). Record assistance level and gait aids.

3-meter walk test at regular base and fast base.

Baseline/preoperative to postoperative day 14
Analgesic consumption
Periodo de tiempo: Baseline/preoperative to postoperative day 14
Opioid consumption: record rescue analgesic use
Baseline/preoperative to postoperative day 14
Quadriceps strength via handheld dynamometry.
Periodo de tiempo: Baseline/preoperative to postoperative day 14

Seated 60 Degrees Knee Flexion Patient position Seated on the edge of the table, with feet not in contact with the ground and knee at 60 degrees of flexion.

Contact point Posterior aspect of the ankle attachment, at the hook closest to the achilles tendon.

Device orientation Horizontal, linked to the ankle strap at one end and anchored to a fixed surface by the cable strap at the other, posterior to the patient's leg being tested.

Position of examiner Adjacent to the patient, in a position to situate the DynaMo and instruct the action.

Instruction Pull against the DynaMo as hard as you can. 3, 2, 1 - pull, pull, pull and relax.

Attachments Tension links, Carabiners, Ankle strap, Tension strap.

Baseline/preoperative to postoperative day 14
Neuromuscular electrical stimulation response
Periodo de tiempo: Baseline/preoperative to postoperative day 14
Neuromuscular electrical stimulation response by chattanoga multi-current electrical stimulation.
Baseline/preoperative to postoperative day 14
Patient satisfaction with postoperative recovery measured by a 5-point Likert Scale
Periodo de tiempo: postoperative day 14
Patient satisfaction with postoperative recovery will be assessed on postoperative day 14 using a 5-point Likert Scale, where 1 = very dissatisfied, 2 = dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = satisfied, and 5 = very satisfied.
postoperative day 14
Serum Interleukin-6 (IL-6)
Periodo de tiempo: Baseline (pre-operative), 24-48 hours post-operative (peak IL-6 window), Baseline/preoperative to postoperative day 14.

Interleukin-6 is a pro-inflammatory cytokine and an early mediator of the surgical stress response. Serum IL-6 will be quantified from peripheral venous blood by ELISA. Higher concentrations indicate a greater systemic inflammatory response; IL-6 peaks at approximately 24-48 hours postoperatively.

Unit: pg/mL · Reference: < 7 pg/mL (assay-dependent)

Baseline (pre-operative), 24-48 hours post-operative (peak IL-6 window), Baseline/preoperative to postoperative day 14.
Hemostasis or clotting tests
Periodo de tiempo: Baseline/preoperative to postoperative day 14
PT (Prothrombin Time) APTT (Activated Partial Thromboplastin Time) D-dimer Fibrinogen
Baseline/preoperative to postoperative day 14
Serum C-Reactive Protein (CRP)
Periodo de tiempo: Baseline (preoperative), postoperative 24-48 hours, and postoperative day 14.

C-reactive protein is a hepatically synthesized acute-phase reactant produced in response to IL-6 signaling. Serum CRP will be measured from peripheral venous blood by immunoturbidimetric assay. Higher concentrations indicate greater systemic inflammation; CRP peaks later than IL-6 (~48-72 hours).

Unit: mg/L · Reference: < 10 mg/L (hs-CRP: < 1 low, 1-3 moderate, > 3 high cardiovascular risk)

Baseline (preoperative), postoperative 24-48 hours, and postoperative day 14.
Serum Interleukin-10 (IL-10)
Periodo de tiempo: Baseline (preoperative), postoperative 24-48 hours, and postoperative day 14.

Interleukin-10 is an anti-inflammatory cytokine mediating the compensatory anti-inflammatory response to surgical injury. Serum IL-10 will be quantified from peripheral venous blood by ELISA. Higher concentrations indicate a greater compensatory anti-inflammatory response.

Unit: pg/mL · Reference: < 10 pg/mL (often < 5 pg/mL; assay-dependent)

Baseline (preoperative), postoperative 24-48 hours, and postoperative day 14.
Serum Tumor Necrosis Factor-alpha (TNF-α)
Periodo de tiempo: Baseline (preoperative), postoperative 24-48 hours, and postoperative day 14.

Tumor necrosis factor-alpha is a pro-inflammatory cytokine released early in the innate immune response to tissue injury. Serum TNF-α will be quantified from peripheral venous blood by ELISA. Higher concentrations indicate a greater pro-inflammatory response.

Unit: pg/mL · Reference: < 8.1 pg/mL (commonly < 15-20 pg/mL; assay-dependent)

Baseline (preoperative), postoperative 24-48 hours, and postoperative day 14.
Prothrombin Time (PT)
Periodo de tiempo: Baseline (preoperative) and postoperative day 14.

Prothrombin time assesses the extrinsic and common coagulation pathways. PT will be determined on platelet-poor plasma (peripheral venous blood in 3.2% sodium citrate) by an automated clot-based method using a thromboplastin reagent. A prolonged PT indicates impaired extrinsic/common-pathway function.

Unit: seconds · Reference: 11-13.5 seconds (INR 0.8-1.1)

Baseline (preoperative) and postoperative day 14.
Activated Partial Thromboplastin Time (APTT)
Periodo de tiempo: Baseline (preoperative) and postoperative day 14.

Activated partial thromboplastin time assesses the intrinsic and common coagulation pathways. APTT will be determined on citrated platelet-poor plasma by an automated clot-based method. A prolonged APTT indicates impaired intrinsic/common-pathway function.

Unit: seconds · Reference: 25-35 seconds

Baseline (preoperative) and postoperative day 14.
D-dimer
Periodo de tiempo: Frame: Baseline (preoperative) and postoperative day 14.

D-dimer is a fibrin degradation product reflecting activation of coagulation and fibrinolysis. D-dimer will be measured on citrated plasma by a latex-enhanced immunoturbidimetric assay. Elevated concentrations indicate increased fibrin turnover (hypercoagulable/prothrombotic state or venous thromboembolism).

Unit: µg/mL FEU · Reference: < 0.50 µg/mL FEU (< 500 ng/mL FEU)

Frame: Baseline (preoperative) and postoperative day 14.
Fibrinogen
Periodo de tiempo: Baseline (preoperative) and postoperative day 14.

Fibrinogen (coagulation factor I) is the soluble precursor of fibrin and an acute-phase reactant. Plasma fibrinogen will be measured on citrated plasma by the Clauss clot-based method. Elevated concentrations reflect an acute-phase/inflammatory response; low concentrations may reflect consumption or dilution and a bleeding tendency.

Unit: mg/dL · Reference: 200-400 mg/dL (2-4 g/L)

Baseline (preoperative) and postoperative day 14.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

16 de junio de 2026

Finalización primaria (Estimado)

1 de mayo de 2027

Finalización del estudio (Estimado)

16 de mayo de 2027

Fechas de registro del estudio

Enviado por primera vez

4 de junio de 2026

Primero enviado que cumplió con los criterios de control de calidad

3 de julio de 2026

Publicado por primera vez (Actual)

7 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

7 de julio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

3 de julio de 2026

Última verificación

1 de marzo de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir